药物临床试验登记与信息公示平台数据显示,江苏康宁杰瑞生物制药有限公司的JSKN016联合D - 0502在局部晚期或转移性HR阳性、HER2阴性乳腺癌患者中的多中心、开放标签、Ib/II期随机对照临床研究已启动。临床试验登记号为CTR20255271,首次公示信息日期为2026年1月4日。该药物剂型为注射液和片剂,JSKN016注射液用法为静脉输注,按4mg/kg剂量给药,Q2W组每14天为1周期...
Source Link药物临床试验登记与信息公示平台数据显示,江苏康宁杰瑞生物制药有限公司的JSKN016联合D - 0502在局部晚期或转移性HR阳性、HER2阴性乳腺癌患者中的多中心、开放标签、Ib/II期随机对照临床研究已启动。临床试验登记号为CTR20255271,首次公示信息日期为2026年1月4日。该药物剂型为注射液和片剂,JSKN016注射液用法为静脉输注,按4mg/kg剂量给药,Q2W组每14天为1周期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.